NUP214 and acute myeloid leukemia: Nonetheless, CRM1 drug-targeted inhibition relocalizes SET-NUP214 and DEK-NUP214 nuclear bodies throughout the nucleoplasm and exerts an anti-leukemic effect in AML with NUP214 rearrangement [8].